3.40
+0.12(+3.66%)
Currency In USD
Address
280 East Grand Avenue
South San Francisco, CA 94080
United States of America
Phone
(650) 231-6625
Website
Sector
Healthcare
Industry
Biotechnology
Employees
168
First IPO Date
February 22, 2021
| Name | Title | Pay | Year Born |
| Mr. Martin Babler Ph.D. | President, Chief Executive Officer & Chairman | 912,638 | 1965 |
| Mr. Roy C. Hardiman J.D. | Chief Business & Strategy Officer | 619,841 | 1960 |
| Dr. David M. Goldstein Ph.D. | Chief Scientific Officer | 651,368 | 1967 |
| Mr. Philip Nunn Ph.D. | Senior Vice President of Pharmacology & Project Team Leader | 0 | N/A |
| Mr. Mark Bradley | Chief Development Officer | 0 | 1966 |
| Ms. Sara Klein | Chief Legal Officer & Corporate Secretary | 0 | 1965 |
| Mr. Derrick Richardson | Senior Vice President of People & Culture | 0 | 1971 |
| Ms. Claire Langrish Ph.D. | Senior Vice President & Head of Immunology and Translational Science | 0 | N/A |
| Dr. Jorn Drappa M.D., Ph.D. | Chief Medical Officer | 0 | 1965 |
| Mr. John R. Schroer C.F.A. | Chief Financial Officer | 0 | 1965 |
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.
